🇪🇺 Cinqair in European Union

EMA authorised Cinqair on 15 August 2016

Marketing authorisations

EMA — authorised 15 August 2016

  • Application: EMEA/H/C/003912
  • Marketing authorisation holder: Teva B.V.
  • Local brand name: Cinqaero
  • Indication: Cinqaero is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.
  • Status: approved

Read official source →

EMA — authorised 16 August 2016

  • Marketing authorisation holder: Teva Pharmaceuticals Limited
  • Status: approved

Cinqair in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Respiratory approved in European Union

Frequently asked questions

Is Cinqair approved in European Union?

Yes. EMA authorised it on 15 August 2016; EMA authorised it on 16 August 2016.

Who is the marketing authorisation holder for Cinqair in European Union?

Teva B.V. holds the EU marketing authorisation.